An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug’s effect on cardiovascular disease and non-alcoholic steatohepatitis

This publication has 58 references indexed in Scilit:

• Comparing Pioglitazone to Insulin with Respect to Cancer, Cardiovascular and Bone Fracture Endpoints, Using Propensity Score Weights
  Clinical Drug Investigation, 2013
• Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studies
  Diabetic Medicine, 2013
• Does Insulin Resistance Drive the Association between Hyperglycemia and Cardiovascular Risk?
  PLOS ONE, 2012
• Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
  Diabetologia, 2012
• The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
  Diabetes & Metabolism Journal, 2012
• Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus
  Hepatology, 2011
• Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
  Diabetes Care, 2011
• Role of Pioglitazone in the Prevention of Restenosis and Need for Revascularization After Bare-Metal Stent Implantation
  JACC: Cardiovascular Interventions, 2011
• Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
  New England Journal of Medicine, 2010
• Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke
  Stroke, 2007